Neuro-Bio’s CEO, Susan Greenfield, had a very personal and interesting interview for the Australian Financial Review. Click the link to read the full article.
During the EAN 2022 Annual Congress, Neuro-Bio’s CEO Susan Greenfield participated at the 8th edition of Challenges for women in neurology. She closed the networking event with a lecture about her journey within neuroscience as a woman. To read more...
Neuro-Bio Ltd welcomes Joanna Komorowska as new intern. Joanna is a third-year student of Neuroscience with Psychology at the University of Aberdeen, originally from Poland. She is interested in neurogenerative diseases and how they affect the human body and mind. For...
Neuro-Bio Ltd welcomes Amy-May Pointer as new Laboratory Manager. Amy-May graduated from the University of Nottingham with a Bachelor Honours degree in Microbiology. Her final-year research project focused on Extended-Spectrum Beta-Lactamases (ESBL) Producing...
Susan Greenfield, Founder and CEO of Neuro-Bio Ltd, shared her insights on the challenges of developing Alzheimer’s disease treatments, and the fundamental flaw with approaches to date on the “European Biopharmaceutical Review”. To read the full article,...
On Saturday the 25th of June, Neuro-Bio’s CEO Susan Greenfield, will speak at the opening session of the EAN 2022 congress, the biggest meeting in Neurology! Her talk will be “Where Neuroscience meets neurology: blowing, expanding, and losing the...
During her trip to Australia, Neuro-Bio’s CEO, Susan Greenfield had an interview with Julie Hare, Education editor for the Australian “Financial Review”. In April, Baroness Professor Greenfield published a research paper that proved a drug developed...
On Monday the 30th of May, Neuro-Bio’s operations director, Sara Garcia-Rates, will be presenting at virtual AIMday in Translational Dementia Research, hosted by the University of Oxford. Sara will be talking about Neuro-Bio’s research in a workshop from 10.15...
